Caribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy Programs

Caribou Biosciences, Inc. (Nasdaq: CRBU) is exploring strategic alternatives to enhance shareholder value and will cease development of its two allogeneic CAR-T cell therapy programs, vispa-cel and CB-011. The company plans to implement workforce and cost reductions as part of this decision.